WG
CHRS icon

Winton Group’s Coherus Oncology CHRS Stock Holding History

Winton Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-27,761
Closed -$443K – 979
2021
Q4 		$443K Sell
27,761
-32,478
-54% -$568K 0.03% 706
2021
Q3 		$968K Sell
60,239
-16,422
-21% -$241K 0.05% 522
2021
Q2 		$1.06M Buy
76,661
+8,617
+13% +$122K 0.06% 496
2021
Q1 		$994K Buy
68,044
+11,709
+21% +$199K 0.06% 463
2020
Q4 		$979K Sell
56,335
-58,660
-51% -$1.04M 0.07% 415
2020
Q3 		$2.11M Buy
114,995
+63,271
+122% +$1.18M 0.07% 502
2020
Q2 		$924K Buy
+51,724
New +$875K 0.02% 999

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Winton Group's CHRS Position: Q1 2022 in Review

Winton Group sold out of Coherus Oncology (CHRS) in Q1 2022, closing a stake of 27,761 shares — an estimated $443K sold.

Winton Group first reported a position in CHRS in Q2 2020 and held it in 7 quarters. The position peaked at $2.11M in Q3 2020. 183 funds tracked by Wall St. Rank hold CHRS as of Q1 2022.

  • Winton Group reported no remaining Coherus Oncology position as of Q1 2022 after selling out during the quarter.
  • Winton Group sold 27,761 Coherus Oncology shares in Q1 2022, an estimated $443K.
  • Winton Group first reported a position in Coherus Oncology in Q2 2020 and held it in 7 quarters.
  • Winton Group's Coherus Oncology position peaked at $2.11M in Q3 2020.
  • 183 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2022.

Based on Winton Group's 13F filing for Q1 2022, filed 11 May 2022.